中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

58 records (took 0.025 seconds)

    遺伝子治療用脂肪細胞の調製のための外来遺伝子の導入に適した細胞集団かどうかを判定する方法
    3.
    发明申请
    遺伝子治療用脂肪細胞の調製のための外来遺伝子の導入に適した細胞集団かどうかを判定する方法 审中-公开
    用于确定不是细胞人口的方法适用于外源基因转移用于基因治疗应用的ADIPOCYTES的制备目的

    公开(公告)号：WO2011090091A1

    公开(公告)日：2011-07-28

    申请号：PCT/JP2011/050919

    申请日：2011-01-20

    Applicant: セルジェンテック株式会社 ,  国立大学法人千葉大学 ,  麻生 雅是 ,  武城 英明 ,  齋藤 康 ,  黒田 正幸

    Inventor： 麻生　雅是 ,  武城　英明 ,  齋藤　康 ,  黒田　正幸

    IPC: C12N5/10 ,  C12Q1/02 ,  G01N33/483 ,  G01N33/53 ,  G01N33/533 ,  C12N15/09

    CPC classification number: G01N33/5044 ,  G01N2333/70525

    Abstract: 　本発明の課題は、ウイルスベクターを用いて外来遺伝子を導入してなる遺伝子治療のための脂肪細胞の調製に際し、外来遺伝子の導入に適した細胞集団かどうかを判定する方法を提供することである。その解決手段としての本発明は、ＣＤ５４の発現の程度を指標にしてその発現程度が低いほど適していると判定するものである。外来遺伝子の導入に適した脂肪細胞の細胞集団としては、蛍光抗体を用いたフローサイトメトリー法によって測定されるＣＤ５４の発現陽性率が３％未満および／またはＣＤ５４の平均蛍光強度比が２未満である細胞集団が挙げられる。

    Abstract translation: 公开了一种用于确定脂肪细胞是否是适合于在用于基因治疗的脂肪细胞制备中的外源基因的基因转移的细胞群，包括使用病毒载体导入外源基因。 在该方法中，基于CD54在脂肪细胞中的表达水平确定适合性，并且确定具有较低CD54表达水平的脂肪细胞是适合的。 适合于外源基因转移的脂肪细胞的细胞群的例子是CD54表达的阳性率小于3％的细胞群和/或CD54的平均荧光强度比小于2，如 使用荧光抗体的流式细胞术。

    NON-INVASIVE DIAGNOSTIC AGENTS AND METHODS OF DIAGNOSING INFECTIOUS DISEASE
    5.
    发明申请
    NON-INVASIVE DIAGNOSTIC AGENTS AND METHODS OF DIAGNOSING INFECTIOUS DISEASE 审中-公开
    非侵入性诊断试剂和诊断感染性疾病的方法

    公开(公告)号：WO2009151646A2

    公开(公告)日：2009-12-17

    申请号：PCT/US2009003569

    申请日：2009-06-15

    Applicant: STC UNM ,  NORENBERG JEFFREY P

    Inventor： NORENBERG JEFFREY P

    IPC: A61K51/00 ,  A61K31/4178 ,  A61K103/20 ,  A61K103/34 ,  A61P31/00 ,  A61P31/04

    CPC classification number: A61K51/0453 ,  A61K31/4178 ,  A61K51/00 ,  A61K51/044 ,  A61K51/0497 ,  G01N33/569 ,  G01N2333/70525 ,  G01N2333/70553

    Abstract: The present invention is directed to novel non-invasive diagnostic tools to diagnose numerous infectious disease states or conditions. The present invention represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these disease states. The novel imaging probe is capable of detecting infected cells, as well tissue. This represents a quantum step forward in the diagnosis and staging of NHL using non-invasively molecular imaging techniques. This novel probe will also be useful to monitor patients response to therapeutic treatments and other interventions or therapies used in the treatment of these disease states or conditions. Compounds according to the present invention may be used as diagnostic tools for a number of conditions and diseases states as well as therapeutic agents for treating such conditions and disease states. Pharmaceutical compositions are also described.

    Abstract translation: 本发明涉及用于诊断许多传染病状态或病症的新型非侵入性诊断工具。 本发明代表了本领域的显着进步，其目前依赖于组织活检以诊断这些疾病状态。 该新型成像探针能够检测感染的细胞以及组织。 这代表了使用非侵入性分子成像技术在NHL的诊断和分期中向前推进的量子进程。 这种新型探针也可用于监测患者治疗治疗和治疗这些疾病状态或病症的其他干预措施或疗法的反应。 根据本发明的化合物可以用作许多病症和疾病状态的诊断工具以及用于治疗这些病症和疾病状态的治疗剂。 还描述了药物组合物。

    METHODS AND COMPOSITIONS FOR DETECTING RARE CELLS FROM A BIOLOGICAL SAMPLE
    6.
    发明申请
    METHODS AND COMPOSITIONS FOR DETECTING RARE CELLS FROM A BIOLOGICAL SAMPLE 审中-公开
    从生物样品中检测稀有细胞的方法和组合物

    公开(公告)号：WO2008008515A3

    公开(公告)日：2008-11-06

    申请号：PCT/US2007016034

    申请日：2007-07-14

    Applicant: AVIVA BIOSCIENCES CORP ,  LIN PING ,  GHETTI ANDREA ,  SHI WENGE ,  TANG MENGJIA ,  HARVIE GIOULNAR ,  TAO HUIMIN ,  TAO GUOLIANG ,  WU LEI ,  CERNY DAVID ,  XU JIA

    Inventor： LIN PING ,  GHETTI ANDREA ,  SHI WENGE ,  TANG MENGJIA ,  HARVIE GIOULNAR ,  TAO HUIMIN ,  TAO GUOLIANG ,  WU LEI ,  CERNY DAVID ,  XU JIA

    IPC: C12Q1/04

    CPC classification number: C12N5/0693 ,  G01N33/5094 ,  G01N33/54346 ,  G01N33/56972 ,  G01N33/574 ,  G01N2015/1006 ,  G01N2015/1402 ,  G01N2333/70525 ,  G01N2333/70589 ,  G01N2800/52 ,  Y10T436/25375

    Abstract: The invention provides methods and compositions for isolating and detecting rare cells from a sample containing other types of cells. In particular, the invention includes a debulking step that can use a microfabricated filter or a cell lysis step or density-based methods to remove certain types of cells, and immobilization methods to remove other types of cells. The invention also includes a method for determining the number or proportion of cancer cells in a biological sample by detecting the presence or amount of telomerase activity or telomerase nucleic acid or telomerase expression after enrichment of rare cells. This invention further provides an efficient and rapid method to specifically remove red blood cells as well as white blood cells from a biological sample, resulting in the enrichment of rare target cells. The presence or level of target cells provides information about various physiological conditions, such as cancer.

    Abstract translation: 本发明提供了用于从含有其他类型的细胞的样品中分离和检测稀有细胞的方法和组合物。 具体而言，本发明包括可使用微制造的过滤器或细胞裂解步骤或基于密度的方法来移除某些类型的细胞的去模糊步骤，以及移除其他类型的细胞的固定方法。 本发明还包括通过检测富集稀有细胞后端粒酶活性或端粒酶核酸或端粒酶表达的存在或量来确定生物样品中癌细胞的数量或比例的方法。 本发明进一步提供了从生物样品中特异性去除红细胞和白血细胞的有效和快速的方法，导致稀有靶细胞的富集。 靶细胞的存在或水平提供关于各种生理状况的信息，例如癌症。

    TERTIARY STRUCTURES OF ICA-1/LFA-1 MODULATORS
    7.
    发明申请
    TERTIARY STRUCTURES OF ICA-1/LFA-1 MODULATORS 审中-公开
    ICA-1 / LFA-1调制器的初步结构

    公开(公告)号：WO2005007821A2

    公开(公告)日：2005-01-27

    申请号：PCT/US2004/021861

    申请日：2004-07-07

    Applicant: SCIENCE & TECHNOLOGY CORPORATION @ UNM ,  LARSON, Richard, S. ,  SILLERUD, Laurel

    Inventor： LARSON, Richard, S. ,  SILLERUD, Laurel

    IPC: C12N

    CPC classification number: C07K7/06 ,  G01N2333/70525

    Abstract: The invention provides tertiary structures) of cyclic nonapeptide ICAM-1 inhibitors and methods of using the tertiary structures tp identify additional ICAM-1 inhibitors, particularly non-peptide modulators. The invention also provides methods of treating ICAM­1/LFA-1 mediated diseases comprising administ4ring a non-peptide ICAM-1 modulator of the invention to a patient in need thereof.

    Abstract translation: 本发明提供三级结构）的环状肽IIICAM-1抑制剂和使用三级结构tp的方法鉴定另外的ICAM-1抑制剂，特别是非肽调节剂。 本发明还提供了治疗ICAM1 / LFA-1介导的疾病的方法，其包括向有需要的患者施用本发明的非肽ICAM-1调节剂。

    PRIMITIVE AND PROXIMAL HEPATIC STEM CELLS
    9.
    发明申请
    PRIMITIVE AND PROXIMAL HEPATIC STEM CELLS 审中-公开
    主要和临床干细胞

    公开(公告)号：WO03078588A9

    公开(公告)日：2003-12-11

    申请号：PCT/US0307852

    申请日：2003-03-14

    Applicant: UNIV NORTH CAROLINA ,  INCARA CELL TECHNOLOGIES INC ,  REID LOLA ,  MOSS NICHOLAS G ,  FURTH MARK E ,  LUDLOW JOHN W ,  BRUCE ANDREW T

    Inventor： REID LOLA ,  MOSS NICHOLAS G ,  FURTH MARK E ,  LUDLOW JOHN W ,  BRUCE ANDREW T

    IPC: C12N5/071 ,  A61K35/12 ,  A61K35/48 ,  A61P1/16 ,  C12N5/074 ,  C12N5/0789 ,  C12N5/10 ,  C12N

    CPC classification number: C12N5/0672 ,  C12N2500/25 ,  C12N2500/36 ,  C12N2500/90 ,  C12N2501/11 ,  C12N2502/13 ,  G01N33/5005 ,  G01N33/68 ,  G01N2333/705 ,  G01N2333/70525 ,  G01N2333/70596

    Abstract: Hepatic progenitors comprise two populations of human hepatic stem cells, primitive and proximal hepatic stem cells, and two populations of committed progenitors, one for biliary cells and one for hepatocytes. Human primitive hepatic stem cells are a very small fraction of the liver cell population and give rise to proximal hepatic stem cells constituting a much larger fraction of the liver. Human proximal hepatic stem cells give rise to biliary and hepatocyte committed progenitors. Primitive and proximal stem cells are the primary stem cells for the human liver. Human primitive hepatic stem cells may be isolated by immunoselection from human livers or culturing human liver cells under conditions which select for a human primitive hepatic stem cell. Proximal hepatic stem cells may be isolated by immunoselection, or by culturing human liver cells under conditions which include a developmental factor. Proximal hepatic stem cells may also be isolated by culturing colonies comprising a primitive hepatic stem cell under conditions which include a developmental factor. Resulting compositions may be used for treating liver disorders and for producing bioartificial organs.

    Abstract translation: 肝祖细胞包含两个人类肝干细胞，原始和近端肝干细胞，以及两个定型祖细胞群，一个为胆汁细胞，一个为肝细胞。 人原始肝干细胞是肝细胞群体的非常小的一部分，并且引起近端肝干细胞构成肝脏的大部分。 人近端肝干细胞产生胆汁和肝细胞定向的祖细胞。 原始和近端干细胞是人类肝脏的主要干细胞。 人原始肝干细胞可以通过人肝脏的免疫选择或在选择人原始肝干细胞的条件下培养人肝细胞来分离。 可以通过免疫选择或通过在包括发育因子的条件下培养人肝细胞来分离近端肝干细胞。 也可以通过在包括发育因子的条件下培养包含原始肝干细胞的菌落来分离近端肝干细胞。 所得组合物可用于治疗肝脏疾病和生产生物人造器官。

    PRIMITIVE AND PROXIMAL HEPATIC STEM CELLS
    10.
    发明申请
    PRIMITIVE AND PROXIMAL HEPATIC STEM CELLS 审中-公开
    原始和近端肝脏干细胞

    公开(公告)号：WO2003078588A2

    公开(公告)日：2003-09-25

    申请号：PCT/US2003/007852

    申请日：2003-03-14

    Applicant: UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL ,  INCARA CELL TECHNOLOGIES, INC. ,  REID, Lola ,  MOSS, Nicholas, G. ,  FURTH, Mark, E. ,  LUDLOW, John, W. ,  BRUCE, Andrew, T.

    Inventor： REID, Lola ,  MOSS, Nicholas, G. ,  FURTH, Mark, E. ,  LUDLOW, John, W. ,  BRUCE, Andrew, T.

    IPC: C12N

    CPC classification number: C12N5/0672 ,  C12N2500/25 ,  C12N2500/36 ,  C12N2500/90 ,  C12N2501/11 ,  C12N2502/13 ,  G01N33/5005 ,  G01N33/68 ,  G01N2333/705 ,  G01N2333/70525 ,  G01N2333/70596

    Abstract: Hepatic progenitors comprise two populations of human hepatic stem cells, primitive and proximal hepatic stem cells, and two populations of committed progenitors, one for biliary cells and one for hepatocytes. Human primitive hepatic stem cells are a very small fraction of the liver cell population and give rise to proximal hepatic stem cells constituting a much larger fraction of the liver. Human proximal hepatic stem cells give rise to biliary and hepatocyte committed progenitors. Primitive and proximal stem cells are the primary stem cells for the human liver. Human primitive hepatic stem cells may be isolated by immunoselection from human livers or culturing human liver cells under conditions which select for a human primitive hepatic stem cell. Proximal hepatic stem cells may be isolated by immunoselection, or by culturing human liver cells under conditions which include a developmental factor. Proximal hepatic stem cells may also be isolated by culturing colonies comprising a primitive hepatic stem cell under conditions which include a developmental factor. Resulting compositions may be used for treating liver disorders and for producing bioartificial organs.

    Abstract translation: 肝祖细胞包含两个人肝干细胞群体，原始和近端肝干细胞以及两个定向祖细胞群体，一个用于胆道细胞，一个用于肝细胞。 人类原始肝干细胞是肝细胞群中非常小的一部分，并且产生构成肝的大部分的肝近端干细胞。 人类近端肝干细胞产生胆汁和肝细胞定向祖细胞。 原始和近端干细胞是人类肝脏的主要干细胞。 人类原始肝干细胞可以通过从人肝脏免疫选择或在选择人原始肝干细胞的条件下培养人肝细胞来分离。 近端肝干细胞可以通过免疫选择或通过在包括发育因子的条件下培养人肝细胞来分离。 通过在包含发育因子的条件下培养包含原始肝干细胞的集落也可以分离近端肝干细胞。 所得的组合物可用于治疗肝脏疾病和生产人造器官。

Patent Agency Ranking